Analytical Data
-
Gene name
Short chain dehydrogenase
- Application
-
Alternative Names
Lentilactobacillus buchneri subsp. silagei CD034; Oxidoreductase
-
Species
Others
-
Source
E. coli
-
Tag
His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
J9VYK8
-
Expression Region
M1-W248
-
Protein Length
Full Length
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Short chain dehydrogenases (SCDs) represent a diverse family of enzymes that play crucial roles in various biological processes, including metabolism, steroidogenesis, and the detoxification of drug and xenobiotic compounds. These enzymes are capable of catalyzing the oxidation or reduction of a variety of substrates, such as alcohols, aldehydes, and ketones, utilizing NAD(P)+ as a cofactor. Due to their significant physiological and biomedical implications, including their involvement in metabolic disorders and cancer, characterizing SCDs at the molecular level is essential. The study of recombinant SCD proteins allows researchers to elucidate their structure-function relationships, investigate their enzymatic mechanisms, and explore their potential applications in biotechnology and pharmaceuticals. By employing techniques such as gene cloning, expression in heterologous systems, and subsequent purification, scientists can produce sufficient quantities of these enzymes for detailed biochemical and biophysical studies. Additionally, understanding the regulatory elements and substrate specificity of SCDs can aid in the development of targeted therapeutics and biocatalysts for industrial processes. Overall, the research on recombinant short chain dehydrogenases fosters a deeper understanding of their roles in health and disease, paving the way for innovative approaches to tackle metabolic and therapeutic challenges.
